Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D19RKX
|
|||
| Drug Name |
Zinpentraxin alfa
|
|||
| Drug Type |
Protein
|
|||
| Indication | Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Phase 3 | [1] | |
| Company |
Roche/Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serum amyloid P-component (APCS) | Target Info | Replacement | [2] |
| Reactome | Amyloid formation | |||
| WikiPathways | Human Complement System | |||
| Amyloids | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04552899) A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis. U.S.National Institutes of Health. | |||
| REF 2 | Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica. 2023 Oct 1;108(10):2730-2742. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.